Stockscreener 앱 받기
314.40
1.92%
5.92
전일 마감가:
$308.48
열려 있는:
$302.55
하루 거래량:
1.39M
Relative Volume:
0.94
시가총액:
$41.54B
수익:
$3.21B
순이익/손실:
$43.57M
주가수익비율:
1,307.28
EPS:
0.2405
순현금흐름:
$221.36M
1주 성능:
-4.19%
1개월 성능:
-15.02%
6개월 성능:
-27.31%
1년 성능:
+18.69%
1일 변동 폭
$302.55
$318.44
1주일 범위
$298.00
$329.92
52주 변동 폭
$205.87
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
명칭
Alnylam Pharmaceuticals Inc
전화
(617) 551-8200
주소
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY vs VRTX, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2026-01-07 | 재개 | Oppenheimer | Outperform |
| 2025-08-04 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-08-04 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | 재개 | Raymond James | Outperform |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-03-31 | 개시 | Redburn Atlantic | Buy |
| 2025-03-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-11-12 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-08-16 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-02-16 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-08 | 개시 | Wells Fargo | Equal Weight |
| 2023-10-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-09-29 | 개시 | Raymond James | Outperform |
| 2023-05-05 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | 개시 | SMBC Nikko | Neutral |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-01-18 | 개시 | Canaccord Genuity | Buy |
| 2022-09-09 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-06-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-06-07 | 개시 | William Blair | Outperform |
| 2022-04-25 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | 개시 | Citigroup | Buy |
| 2022-02-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-01-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | 업그레이드 | Goldman | Neutral → Buy |
| 2021-11-22 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-10-04 | 업그레이드 | UBS | Neutral → Buy |
| 2021-08-04 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-02-12 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-02-12 | 재확인 | H.C. Wainwright | Buy |
| 2021-01-25 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | 재개 | Berenberg | Hold |
| 2020-09-08 | 개시 | Citigroup | Buy |
| 2020-08-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-05-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-04-24 | 재개 | Evercore ISI | Outperform |
| 2020-03-19 | 개시 | Berenberg | Buy |
| 2019-12-19 | 재확인 | Chardan Capital Markets | Buy |
| 2019-11-20 | 개시 | Oppenheimer | Outperform |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-05-23 | 재개 | Goldman | Neutral |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-03-05 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | 개시 | UBS | Neutral |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-08-13 | 재확인 | Stifel | Buy |
| 2018-08-07 | 업그레이드 | Stifel | Hold → Buy |
| 2018-05-04 | 재확인 | Stifel | Hold |
| 2018-03-28 | 개시 | Evercore ISI | In-line |
모두보기
Alnylam Pharmaceuticals Inc 주식(ALNY)의 최신 뉴스
Is Alnylam Pharmaceuticals (ALNY) one of the best upside stocks to invest in right now? - MSN
Is Alnylam Pharmaceuticals (ALNY) One of the Best Upside Stocks to Invest In Right Now? - Finviz
Is It Time To Revisit Alnylam Pharmaceuticals (ALNY) After The Recent Share Price Pullback? - simplywall.st
Alnylam Hit Hard As Investors Forced To Revise Future Profit Expectations (ALNY) - Seeking Alpha
RBC Capital lowers Alnylam Pharmaceuticals stock price target on short-term headwinds - Investing.com Canada
ALNY Q4 Earnings Beat, Sales Miss Despite Y/Y Growth, Stock Down - Bitget
Demystifying Alnylam Pharmaceuticals: Insights From 13 Analyst Reviews - Benzinga
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q4 2025 Earnings Call Transcript - Insider Monkey
RBC Lowers Price Target on Alnylam Pharmaceuticals to $450 From $465, Keeps Outperform Rating - marketscreener.com
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Lowered to $425.00 at Chardan Capital - MarketBeat
Is It Time To Reassess Alnylam Pharmaceuticals (ALNY) After The Recent Share Price Pullback - Yahoo Finance
Is Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) ROE Of 19% Impressive? - Yahoo Finance
Rhumbline Advisers Sells 3,988 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
RNA Therapeutics Market Set to Boom: Strategic Insights - openPR.com
Why Alnylam Pharmaceuticals Stock Slipped Today - The Globe and Mail
Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT In - GuruFocus
Alnylam turns a profit for first time in 24-year history - The Business Journals
Earnings Call Summary | Alnylam Pharmaceuticals(ALNY.US) Q4 2025 Earnings Conference - 富途牛牛
Alnylam Pharmaceuticals Inc (ALNY) Q4 2025 Earnings Call Highlig - GuruFocus
Earnings roundup: Neurocrine slumps, Alnylam battles skeptics and Ascendis eyes a competitor - BioPharma Dive
Alnylam targets 25% revenue CAGR through 2030 amid AMVUTTRA launch momentum and pipeline expansion - MSN
Alnylam Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Alnylam Pharmaceuticals (ALNY) Valuation Check After Swing To Profit On Strong 2025 Earnings - simplywall.st
ALNY: Needham Maintains Buy Rating with Lowered Price Target | A - GuruFocus
Needham & Company LLC Has Lowered Expectations for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Issues Quarterly Earnings Results - MarketBeat
Earnings call transcript: Alnylam Q4 2025 beats EPS, misses revenue forecast - Investing.com Nigeria
Alnylam Pharmaceuticals (ALNY) Projects Significant Revenue Grow - GuruFocus
Earnings call transcript: Alnylam Q4 2025 beats EPS, misses revenue forecast By Investing.com - Investing.com India
Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance - FinancialContent
Here's What Key Metrics Tell Us About Alnylam (ALNY) Q4 Earnings - Yahoo! Finance Canada
Alnylam Pharmaceuticals (ALNY) Q4 Earnings Miss Estimates - GuruFocus
Alnylam: Q4 Earnings Snapshot - kens5.com
Alnylam Pharmaceuticals (ALNY) Surpasses Q4 Earnings Estimates - Yahoo Finance
Alnylam: Fourth Quarter Financial Highlights - Bitget
ALNYLAM PHARMACEUTICALS ($ALNY) Releases Q4 2025 Earnings - Quiver Quantitative
Alnylam Pharmaceuticals Q4 Adjusted Net Income, Revenue Rise; Issues 2026 Outlook - marketscreener.com
Earnings Flash (ALNY) Alnylam Pharmaceuticals, Inc. Posts Q4 Adjusted EPS $1.25 per Share - marketscreener.com
Earnings Flash (ALNY) Alnylam Pharmaceuticals, Inc. Reports Q4 Revenue $1.10B, vs. FactSet Est of $1.15B - marketscreener.com
ALNYLAM PHARMACEUTICALS, INC. SEC 10-K Report - TradingView
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - TradingView
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress - Yahoo Finance
Krilogy Financial LLC Acquires New Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Is Alnylam Pharmaceuticals Inc impacted by rising ratesPortfolio Gains Report & Weekly High Return Stock Forecasts - baoquankhu1.vn
Alnylam earnings ahead: Can blockbuster TTR drug deliver? By Investing.com - Investing.com Canada
Will Alnylam Pharmaceuticals Inc. stock return to pre crisis levels2025 Price Momentum & Stepwise Entry/Exit Trade Alerts - mfd.ru
Envestnet Asset Management Inc. Has $54.25 Million Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Countdown to Alnylam (ALNY) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS - Yahoo Finance
Does Alnylam Pharmaceuticals (NASDAQ:ALNY) Have A Healthy Balance Sheet? - Yahoo Finance
Candriam S.C.A. Reduces Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Alnylam Pharmaceuticals Inc (ALNY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Alnylam Pharmaceuticals Inc 주식 (ALNY) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Greenstreet Yvonne | Chief Executive Officer |
Jan 12 '26 |
Sale |
362.86 |
9,577 |
3,475,157 |
78,411 |
| Poulton Jeffrey V. | EVP, Chief Financial Officer |
Jan 12 '26 |
Sale |
362.87 |
2,780 |
1,008,766 |
57,465 |
| Tanguler Tolga | EVP, Chief Commercial Officer |
Jan 12 '26 |
Sale |
362.87 |
1,510 |
547,927 |
29,728 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Jan 13 '26 |
Sale |
370.33 |
2,290 |
848,065 |
21,264 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Jan 12 '26 |
Sale |
362.87 |
1,510 |
547,927 |
23,554 |
0.10%
1.77%
자본화:
|
볼륨(24시간):